Charles Schwab Investment Management Inc. Boosts Position in Masimo Co. (NASDAQ:MASI)

Charles Schwab Investment Management Inc. grew its holdings in shares of Masimo Co. (NASDAQ:MASI) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 377,836 shares of the medical equipment provider’s stock after buying an additional 7,808 shares during the period. Charles Schwab Investment Management Inc. owned 0.71% of Masimo worth $62,456,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new position in shares of Masimo during the fourth quarter valued at approximately $46,000. Jones Financial Companies Lllp purchased a new position in shares of Masimo during the fourth quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Masimo during the fourth quarter valued at approximately $67,000. Smartleaf Asset Management LLC increased its stake in shares of Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 60 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in shares of Masimo during the fourth quarter valued at approximately $7,733,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Trading Up 0.7 %

NASDAQ MASI opened at $167.67 on Thursday. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The stock has a market cap of $9.05 billion, a P/E ratio of 115.63 and a beta of 1.03. The stock’s fifty day moving average price is $174.96 and its 200-day moving average price is $156.95. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. As a group, equities analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 9.70% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Raymond James lifted their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler lifted their price target on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Wells Fargo & Company lifted their price target on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus target price of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.